Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,729,302 papers from all fields of science
Search
Sign In
Create Free Account
tivantinib
Known as:
c-Met Inhibitor ARQ 197
An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
ARQ 197
MET protein, human
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Tivantinib for the treatment of hepatocellular carcinoma
J. Best
,
C. Schotten
,
Gregor Lohmann
,
G. Gerken
,
A. Dechêne
Expert Opinion on Pharmacotherapy
2017
Corpus ID: 13471661
ABSTRACT Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with a poor…
Expand
2015
2015
Nivolumab for advanced squamous cell lung cancer: what are the next steps?
R. D. De Mello
,
I. Pousa
,
D. Pereira
The Lancet Oncology
2015
Corpus ID: 206142199
Review
2015
Review
2015
Tivantinib for hepatocellular carcinoma
L. Rimassa
,
N. Personeni
,
A. Santoro
2015
Corpus ID: 73123621
Introduction: Hepatocellular carcinoma (HCC) is an aggressive primary tumor of the liver. It mostly occurs in patients with…
Expand
Review
2014
Review
2014
Tivantinib: critical review with a focus on hepatocellular carcinoma
E. Rota Caremoli
,
R. Labianca
Expert Opinion on Investigational Drugs
2014
Corpus ID: 23302362
Introduction: Sorafenib is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib is an…
Expand
2014
2014
Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
L. Leon
,
M. Gemelli
,
R. Sciarrillo
,
A. Avan
,
N. Funel
,
E. Giovannetti
Current Drug Targets
2014
Corpus ID: 44553603
Malignant pleural mesothelioma (MPM) is a lethal disease with scarce therapeutic options, and preclinical studies on new targeted…
Expand
2013
2013
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
D. Feldman
,
L. Einhorn
,
+8 authors
R. Motzer
Investigational new drugs
2013
Corpus ID: 11122608
SummaryBackground Tivantinib is a selective, small-molecule inhibitor of the MET receptor tyrosine kinase. Preclinical and phase…
Expand
Review
2013
Review
2013
Tivantinib in hepatocellular carcinoma
J. Trojan
,
S. Zeuzem
Expert Opinion on Investigational Drugs
2013
Corpus ID: 207476532
Introduction: Tivantinib (ARQ 197) is a selective, oral MET receptor tyrosine kinase inhibitor with broad-spectrum antitumor…
Expand
2013
2013
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Nobuyuki Yamamoto
,
H. Murakami
,
+9 authors
N. Boku
Annals of Oncology
2013
Corpus ID: 206318688
BACKGROUND Tivantinib (formerly ARQ 197) is a selective inhibitor of c-Met mainly metabolized by CYP2C19. CYP2C19 is known for…
Expand
2013
2013
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter
L. Rimassa
,
J. Bruix
,
M. Broggini
,
A. Santoro
Clinical Cancer Research
2013
Corpus ID: 207606221
We read with interest the article by Basilico and colleagues ([1][1]), testing the in vitro activity of tivantinib. The article…
Expand
2012
2012
Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).
L. Rimassa
,
C. Porta
,
+16 authors
A. Santoro
2012
Corpus ID: 78194202
4006 Background: Tivantinib (T) is a selective, oral inhibitor of c-Met, the tyrosine kinase receptor for hepatocyte growth…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE